Biotech and Academia Explore New Partnership Models to Boost Drug Development

The article notes that declining alternative funding and a drop in research grants are forcing biotech companies and universities to rethink how they collaborate.

At the 2026 Chief Medical Officer Summit 360°, a panel of CMOs and academic leaders discussed these changes and shared concrete examples of how tighter partnerships can keep the pipeline of new therapies moving.

The discussion emphasized that aligning resources, data sharing, and joint development strategies could help sustain innovation despite tighter budgets, ultimately benefiting patients.